Infliximab use in Crohn's disease

被引：10

作者：

Bewtra, M ^{[1
]}

Lichtenstein, GR ^{[1
]}

机构：

[1] Univ Penn Hlth Syst, Div Gastroenterol, Philadelphia, PA 19104 USA

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2005年 / 5卷 / 04期

关键词：

Crohn's disease; inflammatory bowel disease; infliximab;

D O I：

10.1517/14712598.5.4.589

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract. The disease can be quite severe, resulting in hospitalisation, requiring long-term treatment with a variety of medications and frequent surgeries. Infliximab is a chimeric monoclonal antibody directed against tumour necrosis factor, a key cytokine in the inflammatory cascade of many diseases, including Crohn's disease. Numerous studies have shown significant improvement in both clinical and endoscopic luminal and fistulising Crohn's disease with infliximab treatment. The clinical efficacy, indications, safety profile and future of infliximab are reviewed.

引用

页码：589 / 599

页数：11

共 50 条

[41] The impact of preoperative use of infliximab on postoperative complications in patients with Crohn's disease
Shiraki, Manabu
Yamamoto, Takayuki
JOURNAL OF CROHNS & COLITIS, 2012, 6 (10): : 1038 - 1038
[42] Steroid use reduces infusion reactions to infliximab in patients with Crohn's disease
Brzezinski, A
Kumar, J
Lashner, BA
Shen, B
Achkar, JP
GASTROENTEROLOGY, 2003, 124 (04) : A194 - A194
[43] Infliximab use in Crohn's disease: impact on health care resources in the UK
Jewell, DR
Satsangi, J
Lobo, A
Probert, C
Forbes, A
Ghosh, S
Shaffer, J
Frenz, M
Drummond, H
Troy, G
Turner, S
Younge, L
Evans, L
Moosa, M
Rodgers-Gray, B
Buchan, S
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2005, 17 (10) : 1047 - 1052
[44] Patterns of infliximab use among Crohn's disease patients in a community setting
Pressman, Alice R.
Hutfless, Suson
Velayos, Fernando
Fireman, Bruce
Lewis, James D.
Allison, James
Abramson, Oren
Herrinton, Lisa J.
INFLAMMATORY BOWEL DISEASES, 2008, 14 (09) : 1265 - 1272
[45] A "REAL LIVE" EXPERIENCE OF INFLIXIMAB USE FOR CROHN'S DISEASE IN SOUTHERN ITALY
Lo Presti, M.
Privitera, A.
Cappello, M.
Lauria, A.
Principi, M.
Della Valle, N.
Grossi, L.
Fries, W.
DIGESTIVE AND LIVER DISEASE, 2010, 42 : S127 - S127
[46] Evaluating the impact of infliximab use on surgical outcomes in pediatric Crohn's disease
Abbas, Paulette I.
Peterson, Michelle L.
Fallon, Sara C.
Lopez, Monica E.
Wesson, David E.
Walsh, Seema M.
Kellermayer, Richard
Rodriguez, J. Ruben
JOURNAL OF PEDIATRIC SURGERY, 2016, 51 (05) : 786 - 789
[47] A Rare Case of IgA Vasculitis Secondary to Infliximab Use in Crohn's Disease
Vangimalla, Shiva
Mirza, Muhammad U.
Choden, Tenzin
Malhotra, Nidhi
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S1154 - S1155
[48] Healing of Tonsillar Crohn's Disease With Infliximab
Bao, Bo
Harriott, Melissa
Kroeker, Karen I.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (11) : XXXI - XXXII
[49] Guidelines for treatment with infliximab for Crohn's disease
Hommes, D. W.
Oldenburg, B.
van Bodegraven, A. A.
van Hogezand, R. A.
de Jong, D. J.
Romberg-Camps, M. J. L.
van der Woude, J.
Dijkstra, G.
NETHERLANDS JOURNAL OF MEDICINE, 2006, 64 (07): : 219 - 229
[50] Infliximab for the treatment of Crohn's disease: Review and indications for clinical use in Canada
Panaccione, R
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2001, 15 (06) : 371 - 375

← 1 2 3 4 5 →